GeoVax Labs, Inc. New (GOVX) Dividend History

GeoVax Labs, Inc. is a biotechnology company focused on developing innovative vaccines and immunotherapies for infectious diseases and cancers. The company leverages its proprietary MVA-VLP (Modified Vaccinia Ankara-Virus-Like Particle) platform to create candidates aimed at HIV, Ebola, Zika, and COVID-19, among others. GeoVax aims to advance its vaccine candidates through clinical trials to address unmet medical needs globally.

1900 Lake Park Drive, Smyrna, GA, 30080
Phone: 678-384-7220
Website: https://www.geovax.com

Dividend History

GeoVax Labs, Inc. New currently does not pay dividends

Company News

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

EmergingGrowth.com announces the schedule for the 78th Emerging Growth Conference, featuring presentations from various companies across different growth sectors.

GlobeNewswire Inc.

Featured Companies: BNRG GRO IPWR MKTW SKYH UCAR VANI XBP
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Labs, a biotechnology company, announced that its CEO will present at the NobleCon20 conference. The company is developing COVID-19 vaccines and cancer immunotherapies, with its lead clinical programs being GEO-CM04S1 and Gedeptin.

GlobeNewswire Inc.
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax Labs announced progress in its COVID-19 vaccine trials, including the BARDA/Project NextGen Phase 2b trial and upcoming data readouts from existing Phase 2 trials. The company also provided updates on its Gedeptin and GEO-MVA Mpox vaccine programs.

GlobeNewswire Inc.
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax, a biotechnology company, will report its third quarter 2024 financial results and provide a corporate update on November 12, 2024. The company will host a conference call and webcast to discuss the results and provide an update on its clinical programs.

GlobeNewswire Inc.
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax Labs, a biotechnology company, announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 21:53:29 UTC